Story · Medicine & Biotech

FDA approves Cosentyx for adults with polymyalgia rheumatica

3 outlets · first reported by Patient Worthy on · latest · 10 hours of coverage

The FDA has approved the interleukin-17 inhibitor secukinumab for the treatment of adults with polymyalgia rheumatica, expanding the armamentarium for the disease beyond steroids and a single biologic approved in 2023. Secukinumab (Cosentyx, Novartis) is the second biologic approved by the FDA for… (Healio)

Coverage, in order

  1. first Patient Worthy obscure
    FDA Approves RYBREVANT FASPRO for Some Adults With Advanced Head and Neck Cancer

    The under-the-skin treatment received accelerated approval after a clinical trial found that tumors shrank in some participants whose cancer had returned or spread after earlier treatment. Head and neck squamous cell carcinoma, or HNSCC, begins in the thin, flat cells lining areas such as the…

  2. Healio indie
    FDA approves Cosentyx for adults with polymyalgia rheumatica

    The FDA has approved the interleukin-17 inhibitor secukinumab for the treatment of adults with polymyalgia rheumatica, expanding the armamentarium for the disease beyond steroids and a single biologic approved in 2023. Secukinumab (Cosentyx, Novartis) is the second biologic approved by the FDA for…

  3. FDA approves new drug for advanced head and neck squamous cell carcinoma

    The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.